Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

296 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Drug-induced thrombotic microangiopathy: incidence, prevention and management.
Pisoni R, Ruggenenti P, Remuzzi G. Pisoni R, et al. Drug Saf. 2001;24(7):491-501. doi: 10.2165/00002018-200124070-00002. Drug Saf. 2001. PMID: 11444722 Review.
Thrombotic microangiopathy.
Pisoni R, Remuzzi G. Pisoni R, et al. Eur J Intern Med. 2000 Jun;11(3):135-139. doi: 10.1016/s0953-6205(00)00083-2. Eur J Intern Med. 2000. PMID: 10854818
Renoprotective therapy in patients with nondiabetic nephropathies.
Pisoni R, Ruggenenti P, Remuzzi G. Pisoni R, et al. Drugs. 2001;61(6):733-45. doi: 10.2165/00003495-200161060-00003. Drugs. 2001. PMID: 11398906 Review.
How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?
Pisoni R, Remuzzi G. Pisoni R, et al. J Nephrol. 2000 May-Jun;13(3):228-31. J Nephrol. 2000. PMID: 10928301 Review.
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Ruggenenti P, et al. Among authors: pisoni r. Kidney Int. 1998 May;53(5):1209-16. doi: 10.1046/j.1523-1755.1998.00874.x. Kidney Int. 1998. PMID: 9573535 Clinical Trial.
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G. Ruggenenti P, et al. Among authors: pisoni r. Circulation. 2003 Feb 4;107(4):586-92. doi: 10.1161/01.cir.0000047526.08376.80. Circulation. 2003. PMID: 12566371 Clinical Trial.
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.
Ruggenenti P, Perna A, Lesti M, Pisoni R, Mosconi L, Arnoldi F, Ciocca I, Gaspari F, Remuzzi G. Ruggenenti P, et al. Among authors: pisoni r. Kidney Int. 2000 Nov;58(5):2093-101. doi: 10.1111/j.1523-1755.2000.00382.x. Kidney Int. 2000. PMID: 11044230
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G. Ruggenenti P, et al. Among authors: pisoni r. Kidney Int Suppl. 1997 Dec;63:S54-7. Kidney Int Suppl. 1997. PMID: 9407422 Clinical Trial.
Effect of high dose ramipril with or without indomethacin on glomerular selectivity.
Pisoni R, Ruggenenti P, Sangalli F, Lepre MS, Remuzzi A, Remuzzi G. Pisoni R, et al. Kidney Int. 2002 Sep;62(3):1010-9. doi: 10.1046/j.1523-1755.2002.00535.x. Kidney Int. 2002. PMID: 12164885 Clinical Trial.
Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.
Foy CG, Lovato LC, Vitolins MZ, Bates JT, Campbell R, Cushman WC, Glasser SP, Gillespie A, Kostis WJ, Krousel-Wood M, Muhlestein JB, Oparil S, Osei K, Pisoni R, Segal MS, Wiggers A, Johnson KC; SPRINT Study Research Group. Foy CG, et al. Among authors: pisoni r. J Hypertens. 2018 Apr;36(4):904-915. doi: 10.1097/HJH.0000000000001619. J Hypertens. 2018. PMID: 29493562 Free PMC article. Clinical Trial.
296 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page